Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 17579 |
Not provided
Not provided
Not provided
The study was suspended due to lack of study drug
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Biodel | INDUSTRY |
| University of Colorado, Denver | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if the use of Linjeta(tm) insulin when compared to Humalog will result in significantly lower episodes of hyperglycemia and hypoglycemia after a breakfast meal.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Humalog U-100 Insulin | Active Comparator |
| |
| LINjeta U-100 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LINjeta U-100 Insulin | Drug | LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors |
|
| Measure | Description | Time Frame |
|---|---|---|
| The primary endpoint for this first phase is the 3 hour area under the curve from baseline following a standardized breakfast meal. | 2 weeks | |
| The primary endpoint for this second phase is the 3 hour area under the curve from baseline following a standardized breakfast meal in the outpatient setting. | 2 weeks | |
| The primary endpoint for this third phase is daytime (6 am to midnight) average glucose values.is percent of CGMS glucose values in range (70-180 mg/dL) for the third week fo sensor data in each group. | 6 weeks |
Not provided
Not provided
Inclusion Criteria:1)Type 1 diabetes for at least 1 year
The diagnosis of type 1 diabetes is based on the investigator¡-s judgment; C peptide level and antibody determinations are not needed.
2) Age : 18 years old ¨C 49.99 years old 3) Continuous subcutaneous insulin infusion (CSII) therapy for at least 3 months 4) Participant consent demonstrated by signing IRB approved documents 6) HgA1c ¡Ü 9% 7) If participant is female with reproductive potential, willing to avoid pregnancy and pregnancy test negative. Exclusion Criteria:1) Chronic oral steroid use
2) The presence of a significant medical disorder that in the judgment of the investigator will affect the wearing of sensors or the completion of any aspect of the protocol.
3) Known clinical history of celiac disease or inflammatory bowel disease. 4) Participants will have a negative anti-endomysial antibody or anti-tissue transglutaminase antibody within one year of enrollment.
5) Cystic Fibrosis 6) Inpatient psychiatric treatment in the past 6 months. 7) Currently pregnant or lactating, or anticipate getting pregnant in the next one year.
8) Clinical diagnosis of gastroparesis. 9) Insulin binding capacity greater than 10 microunits per litter
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bruce A. Buckingham | Stanford University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94305 | United States | ||
| University of Colorado Denver School of Medicine Barbara Davis Center |
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Humalog U-100 | Drug | Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors |
|
|
| Denver |
| Colorado |
| 80045 |
| United States |